# ClinicalTrials.gov record NCT06234111

> PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06234111-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06234111-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06234111-semaglutide-v1.json
- Content SHA-256: `96f8ee207a9a5b09ee90c00567c18459069e940094ab409ed4959e29ef4b0086`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT06234111 ([`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`](#source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`](#source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`](#source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`](#source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046))

## Sources

<a id="source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046"></a>
- **ClinicalTrials.gov record NCT06234111 · retained source version 2024-12-12:eb3eba9ee046a16d504b2ba39bd99d61407c208c0e48cd630694dacd54193e06** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06234111) (`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06234111." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06234111-semaglutide-v1.json SHA-256: 96f8ee207a9a5b09ee90c00567c18459069e940094ab409ed4959e29ef4b0086.